Triamcinolone (Kenalog): Uses, MOA, Warnings

What is triamcinolone?

Triamcinolone is a glucocorticoid, also known as a corticosteroid. It is used in medicine for its anti-inflammatory effects and for modifying immune responses.

The original content lists these related ingredients or forms: triamcinolone acetonide, triamcinolone diacetate, and triamcinolone hexacetonide.

Brand names mentioned in the United States include Kenalog-40, Zilretta, Azmacort, and Aristocort.

How triamcinolone works

Triamcinolone has a powerful anti-inflammatory effect. Like other glucocorticoids, it may also change certain metabolic processes and modify the immune response.

What triamcinolone is used for

The original content lists several therapeutic uses. These depend on the route of administration and the specific product.

Systemic use by intramuscular injection

• Non-suppurative thyroiditis.
• Inflammatory joint and soft tissue conditions such as osteoarthritis synovitis, rheumatoid arthritis, bursitis, epicondylitis, tenosynovitis, gouty arthritis, psoriatic arthritis, ankylosing spondylitis, and juvenile rheumatoid arthritis.
• Systemic lupus erythematosus and acute rheumatic carditis.
• Severe skin conditions such as pemphigus, erythema multiforme, and severe psoriasis.
• Bronchial asthma, allergic rhinitis, and certain dermatitis conditions.
• Eye and inflammatory conditions such as iritis, iridocyclitis, chorioretinitis, uveitis, optic neuritis, and inflammation of the anterior segment.
• Ulcerative colitis and local enteritis.
• Symptomatic sarcoidosis, berylliosis, aspiration pneumonitis, and acquired hemolytic anemia.
• Palliative treatment of some leukemias and lymphomas in adults and acute leukemia in childhood.
• Edematous states.

Local use by intra-articular injection

• Synovitis of osteoarthritis.
• Rheumatoid arthritis.
• Acute and subacute bursitis.
• Acute gouty arthritis.
• Epicondylitis.
• Non-specific acute tenosynovitis.
• Post-traumatic osteoarthritis.

Dosage information

The original content states that dosing should be individualized according to the disease and the patient’s response.

Systemic use: adults and children over 12 years: recommended initial 60 mg IM deep in the gluteus muscle; usual range 40–100 mg. Children 6–12 years: recommended initial 40 mg.

Local use: intra-articular, intrasynovial, or tendon sheath injection: 2.5–40 mg depending on the joint or area treated, with a maximum of 80 mg.

Because triamcinolone products differ, the exact dose and route should be verified in the official leaflet for the specific formulation.

Contraindications listed in the original content

• Systemic infections.
• Idiopathic thrombocytopenic purpura (IM).
• Hypersensitivity.

Warnings and precautions

The original content highlights several situations that require caution, including older age, hypothyroidism, cirrhosis, ocular herpes simplex, nonspecific ulcerative colitis, diverticulitis, and recent intestinal anastomosis.

Other conditions mentioned include active or latent peptic ulcer, renal failure, acute glomerulonephritis, chronic nephritis, high blood pressure, congestive heart failure, thrombophlebitis, thromboembolism, osteoporosis, Cushing’s syndrome, diabetes mellitus, convulsive disorders, metastatic carcinoma, and myasthenia gravis.

Additional points from the original content:

• In stressful situations, a support dose may be needed to avoid adrenocortical insufficiency.
• Do not use by IV, intradermal, intraocular, epidural, or intrathecal routes.
• It can produce subcapsular cataracts and glaucoma.
• It may cause elevation of blood pressure and retention of salt and water.
• It is not recommended in children under 6 years.
• Varicella and measles may have a more serious or even fatal course; exposure should be avoided.
• Patients infected by strongyloids require special caution.
• Vaccination is not recommended during treatment, according to the original content.
• Risk of anaphylactic reaction and psychiatric disorders is noted.
• Do not inject into unstable joints or inflamed tendon.
• In prolonged treatment, monitor child development and ensure adequate protein intake.
• Gradual suspension of treatment is mentioned in the original content.
• Menstrual irregularities and vaginal bleeding in postmenopausal women may occur.

Kidney failure

The original content advises caution in kidney disorders with fixed or decreased renal filtration rate, as edema may occur.

Drug interactions

The original content lists several possible interactions. These should be checked carefully against the exact product and the patient’s full medication list.

The original content also notes a possible false-negative result in the nitro-blue tetrazolium test for bacterial infection.

Pregnancy and breastfeeding

Pregnancy: The original content says clinical experience is limited and that use should be considered only if the benefit to the mother is greater than the potential risk to the fetus or baby.

Breastfeeding: The original content says use during breastfeeding should be considered only if the potential benefit outweighs the potential risk to the mother and infant. It also notes that other systemic corticosteroids have been found in breast milk.

Side effects reported in the original content

• Infection.
• Headache.
• Cataracts.
• Reaction at the injection site.

What to verify in the official leaflet

Because triamcinolone is available in different formulations, readers should confirm the following in the official product information:

• The exact active ingredient and salt or ester form.
• The route of administration for that product.
• The approved uses for that specific brand.
• The full warning and interaction list.
• Age limits and product-specific precautions.

Safety reminder

If you have been prescribed triamcinolone, use the product exactly as directed on the prescription label and official leaflet. Contact a healthcare professional promptly if you notice signs of infection, unusual eye symptoms, severe mood changes, or a reaction at the injection site.

Do not rely on this page alone for treatment decisions, and do not change how you use a corticosteroid without professional guidance.

FAQ

Sources and reference links

• FDA Medication Guides
• UNII: 1ZK20VI6TY
• ChemIDplus
• DrugPortal
• PubChem CID: 31307
• NCI Thesaurus: C901